ASCO image

Pharma reveals its ASCO presentation data

pharmafile | May 12, 2015 | News story | Research and Development, Sales and Marketing ASCO, AZ, AbbVie, Roche, chicago, data 

AstraZeneca, Genentech and AbbVie have all revealed which cancer drugs they will show data for at The American Society of Clinical Oncology (ASCO) this year.

ASCO will take place in the US from 29 May to 2 June in Chicago, and is traditionally a place for companies to announce the latest results from cancer trials.

In a media briefing last week, AstraZeneca revealed that its ASCO presentations would include data from several studies involving AZD9291, an investigational immuno-oncology drug for the treatment of non-small cell lung cancer (NSCLC) patients who have the T790M resistance mutation.

The medicine has garnered excitement for what the company has called ‘unprecedented’ progression-free survival of 13.5 months in a recent trial.

One of the studies is looking at AZD9291 in combination with other compounds from the company – MEDI4736, AZD6094 and selumetinib, which was granted orphan drug status by the FDA for melanoma last month.

The firm’s portfolio of medicines that treat cancer by repairing damaged DNA strands will also have a strong showing at the conference, with data expected from Lynparza (olaparib) and AZD1775, both of which treat ovarian cancer.

The AZD1775 data will include a study testing it in combination with carboplatin and a ‘late breaking’ abstract for a trial of the compound in combination with both carboplatin and paclitaxel.

Meanwhile, Roche subsidiary Genentech will have a particularly large offering at ASCO, presenting data from 10 of its approved medicines and 10 investigational drugs. Many of these trials focus on immunotherapy and personalised medicine.

“We’re particularly excited about our data in different types of advanced lung cancer,” says Sandra Horning, Genentech’s chief medical officer and head of global product development, “including pivotal data for alectinib and results of the first randomized study of our investigational immunotherapy, MPDL3280A.”

Updated results for the company’s combination of cobimetinib and Zelboraf (vemurafenib) – which is currently under review by both the FDA and the EMA for the treatment of melanoma – will also be presented at ASCO, as will data for established medicines Gazyvara (obinutuzumab), in non-Hodgkin’s lymphoma, and Perjeta (pertuzumab).

Preliminary data on investigational compound venetoclax, which recently received breakthrough therapy designation from the FDA for treating chronic lymphocytic leukaemia (CLL) patients with a specific genome mutation, will also be on show.

Venetoclax is co-developed with AbbVie, who will be revealing data from several of their own investigational treatments at the conference.

This includes a Phase II study of breast cancer DDR drug veliparib in NSCLC, as well as trials of ABT-414 in glioblastoma multiforme and solid tumours, duvelisib in treatment naive CLL, and elotuzumab in multiple myeloma.

George Underwood

Related Content


AbbVie’s Aquipta receives MHRA marketing authorisation

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a …

EC approves Roche’s Evrysdi for babies under two months with SMA

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing …


AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up …

Latest content